melphalan and Stomach-Neoplasms

Randomized controlled trials (RCT) on adjuvant chemotherapy for gastric cancer published in the West and Japan were reviewed. Although several small trials showed positive data, adjuvant chemotherapy for curatively resected gastric cancer has been thought to be ineffective in western countries. Results of Japanese RCTs also have not become evidence of its benefit. Despite this, suggestive data by non-predefined subset analyses of old RCTs have been misread as definitive evidence of benefit because of less understanding of clinical statistics in Japan. As a result most Japanese patients have received postoperative adjuvant chemoimmunotherapy. Recently understanding of clinical trial has spread gradually and well designed RCTs with sufficient sample size have been reported. First of all we have to determine the efficacy of adjuvant chemotherapy by carefully designed RCT using surgery alone arm as control.

Topics: Antineoplastic Combined Chemotherapy Protocols; Chemotherapy, Adjuvant; Cisplatin; Cyclophosphamide; Drug Administration Schedule; Fluorouracil; Gastrectomy; Humans; Melphalan; Meta-Analysis as Topic; Randomized Controlled Trials as Topic; Semustine; Stomach Neoplasms; Tegafur; Uracil

Topics: Adenocarcinoma; Aged; Colonoscopy; Gastroscopy; Humans; Male; Melphalan; Multiple Myeloma; Neoplasms, Second Primary; Prednisolone; Sigmoid Neoplasms; Stomach Neoplasms

Topics: Adult; Aged; Biliary Tract Diseases; Clinical Trials as Topic; Colonic Neoplasms; Drug Evaluation; Female; Fluorouracil; Gastrointestinal Neoplasms; Humans; Male; Melphalan; Middle Aged; Pancreatic Neoplasms; Rectal Neoplasms; Stomach Neoplasms

Matrine has potent antitumor activity against a broad variety of cancer cells and our previous study showed that both autophagy and apoptosis were activated during matrine-induced gastric cancer cell death. The aim of the present study was to determine the significance of autophagy in antineoplastic effects of matrine and the molecular mechanism by which matrine induces autophagy in gastric cancer cells. Western blot analysis showed that exposure of gastric cancer cells to matrine resulted in the extent of autophagy increasing in a dose- and time-dependent manner by detecting micro-tubule-associated protein 1 light chain 3 (LC3). This induction was due to activation of autophagic flux, as supported using the lysosome inhibitor, bafilomycin A1, which produced an accumulation of LC3-II. Propidium iodide staining demonstrated that matrine induced cell death in a dose-dependent manner and the autophagy inhibitor 3-methyladenine (3-MA) or bafilomycin A1 enhanced lethality of matrine against gastric cancer cells. Moreover, after pretreatment with 3-MA, some of the gastric cancer cells treated with matrine exhibited prototypical characteristics of apoptosis by transmission electron microscopy. The ability of 3-MA to increase matrine-induced apoptosis was further confirmed by Annexin V-FITC/PI staining. Also, the combination of matrine and 3-MA was more potent than matrine alone in inhibiting the proliferation of SGC-7901 cells assessed by sulphorhodamine B assay. Furthermore, administration of the pan-caspase inhibitor zVAD-fmk or autophagy inducer rapamycin decreased the matrine-induced cell death. In addition, matrine treatment did not inhibit the phosphorylation of Akt and its downstream effectors mammalian target of rapamycin (mTOR) as well as p70 ribosomal protein S6 kinase (p70S6K), although the levels of the total Akt and mTOR were decreased. These results suggest that autophagy was activated as a protective mechanism against matrine-induced apoptosis and inhibition of autophagy may be an attractive strategy for enhancing the antitumor potential of matrine in gastric cancer.

Topics: Adenine; Alkaloids; Apoptosis; Autophagy; Cell Line, Tumor; Cell Nucleus; Cell Shape; Cell Survival; Drug Synergism; Humans; Immunoglobulin G; Macrolides; Matrines; Melphalan; Microtubule-Associated Proteins; Phosphorylation; Protein Processing, Post-Translational; Proto-Oncogene Proteins c-akt; Quinolizines; Stomach Neoplasms

The goal of this study was to determine whether liver, gastric, or colonic cancer may be suitable targets for chemosaturation therapy with percutaneous hepatic perfusion (CS-PHP) and to assess the feasibility of utilizing other cytotoxic agents besides melphalan in the CS-PHP system.. Forty human cell lines were screened against three cytotoxic chemotherapeutic agents. Specifically, the dose-dependent effect of melphalan, oxaliplatin, and paclitaxel on proliferation and apoptosis in each cell line was evaluated. These agents were also evaluated for their ability to induce apoptosis in normal primary human hepatocytes. A high-dose short-term drug exposure protocol was employed to simulate conditions encountered during CS-PHP.. The average concentration of melphalan required for inducing significant apoptosis was 61 μM, or about 3-fold less than the theoretical concentration of 192 μM, achieved in the hepatic artery during CS-PHP dosing with melphalan. Additionally, we found that gastric cancer cell lines were 2-5 fold more sensitive to apoptosis than liver cancer cell lines to all three compounds, suggesting that in addition to colonic and gastric cancer metastases to the liver, primary gastric cancer may also be amenable to management by CS-PHP using an appropriate therapeutic agent. Significantly, at concentrations that are predicted using the CS-PHP system, these agents caused apoptosis of colonic, gastric, and liver cancer cells but were not toxic to primary human hepatocytes.. The compounds tested are potential candidates for use in the CS-PHP system to treat patients with gastric and colonic metastases, and primary cancer of the liver.

Topics: Antineoplastic Agents; Antineoplastic Agents, Alkylating; Antineoplastic Agents, Phytogenic; Apoptosis; Cell Adhesion; Cell Proliferation; Cells, Cultured; Colonic Neoplasms; Flow Cytometry; Hepatic Artery; Hepatocytes; Humans; Liver Neoplasms; Melphalan; Organoplatinum Compounds; Oxaliplatin; Paclitaxel; Perfusion; Stomach Neoplasms

Increasing the drug concentration in tumors may produce massive tumoral response. By using a variety of hepatic vascular isolation techniques, high concentrations of chemotherapeutic drugs may be achieved in the hepatic vascular bed.. Complete percutaneous isolated hepatic perfusion (IHP) is feasible and safe.. Case series.. The hepatobiliary unit of a university hospital.. Ten patients with irresectable and chemoresistant hepatic tumors were eligible for study participation; 4 patients with hepatic metastases of breast cancer, gastric cancer, colorectal cancer, and cholangiocarcinoma were included.. Patients received 3 successive courses of chemotherapy by IHP. The first course was given at laparotomy, and the next 2 courses were given percutaneously. The interval between courses was 3 to 6 weeks. Each course involved IHP of the liver for 15 to 30 minutes, without oxygenation, with 1 to 3 boluses of melphalan (15 mg).. Morbidity and mortality.. Ten IHPs were performed (4 at laparotomy and 6 percutaneously). Concentrations of melphalan in the extracorporeal circulation were 10 times higher than those in the systemic circulation. Percutaneous IHPs had more leakage than those at laparotomy. However, hepatotoxicity was minimized. One patient experienced hepatic artery thrombosis, and 3 had severe neutropenia. Minor complications included ascites and pleural effusion. No deaths were observed 2 months after the last IHP. One partial response was observed (hepatic metastases of breast cancer).. Percutaneous IHP for intensive chemotherapy is less aggressive and less hepatotoxic than IHP at laparotomy and may be iterative.

Topics: Adenocarcinoma; Antineoplastic Agents; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Breast Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Cholangiocarcinoma; Colorectal Neoplasms; Fatal Outcome; Female; Humans; Laparotomy; Liver Neoplasms; Male; Melphalan; Middle Aged; Radiography, Interventional; Stomach Neoplasms

In this study, intra-peritoneal chemotherapy was performed for advanced gastric cancer with serosal invasion. We assessed the efficacy of the chemotherapy using quantitative genetic diagnosis with peritoneal lavages collected before and after chemotherapy at staging laparoscopy and/or gastrectomy. Cases in which genetic diagnosis of peritoneal lavages showed negative results, or changed from positive to negative after chemotherapy, had a good prognosis. On the other hand, cases in which genetic diagnosis showed positive results after chemotherapy had worse prognosis. Intra-peritoneal chemotherapy may be indicated for patients with a positive genetic diagnosis only and cases becoming negative as a result of this therapy may have a better prognosis.

Topics: Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Humans; Infusions, Parenteral; Laparoscopy; Melphalan; Neoplasm Staging; Peritoneal Lavage; Prognosis; Semustine; Stomach Neoplasms

We report a patient with centroblastic non-Hodgkin's MALT lymphoma of the stomach treated initially with surgery and post-operative chemotherapy and radiotherapy. First relapse was treated with high-dose BEAM chemotherapy and autologous peripheral blood stem cell transplantation (PBSCT). Second, systemic relapse was treated with high-dose BU/CY and second PBSCT. Today, the patient is in complete remission at 27+ months. The case indicates a curative potential for high-dose BU/CY chemotherapy as salvage therapy for relapsed high-grade lymphoma after BEAM and autologous PBSCT. This may have implications for the prevention as well as for the management of lymphoma relapse after high-dose chemotherapy (HDC) and autologous PBSCT.

Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Cisplatin; Combined Modality Therapy; Cyclophosphamide; Cytarabine; Doxorubicin; Epirubicin; Etoposide; Granulocyte Colony-Stimulating Factor; Hematopoietic Stem Cell Transplantation; Humans; Ifosfamide; Injections, Spinal; Lymphoma, B-Cell, Marginal Zone; Male; Melphalan; Methotrexate; Prednisone; Recurrence; Remission Induction; Retreatment; Salvage Therapy; Stomach Neoplasms; Transplantation Conditioning; Tumor Lysis Syndrome; Vincristine

The authors describe 4 cases of multiple myeloma that developed one or more extraskeletal localizations. They have evaluated the relation between the onset of the extraskeletal localizations and the following myeloma characteristics: tumor burden, clinical phase, chemotherapy response, prognostic significance. All the patients showed these localizations in a plateau phase of myeloma. None of the patients had fever, pancytopenia and in no one the performance status worsened. All patients obtained at least a partial reduction of the localization and only the patient with the retro-orbital localization, got worse and died for myeloma. The other three patients are alive and do not show any sign of progression.

Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Cyclophosphamide; Humans; Laryngeal Neoplasms; Male; Melphalan; Middle Aged; Multiple Myeloma; Orbital Neoplasms; Prednisone; Prognosis; Stomach Neoplasms; Testicular Neoplasms; Vincristine

Permanent cell lines and clones established from an untreated patient (AGS cells) with gastric carcinoma, and from a similar patient who had been treated with Adriamycin, 5FU and cytoxan (SII cells) were used in a study that compared their drug and radiation survival sensitivities to their glutathidine (GSH) values. The SII parental cell line was more resistant than the AGS cells in vitro to chlorambucil, ACT D, Adria, Bleo, and X-rays. This greater resistance was positively correlated with GSH values that were 1.77 times higher than in the AGS parental cell line. By contrast the SII parental cells were more sensitive than the AGS cells to MeCCNU and Melphalan. The drug and radiation sensitivities expressed among the clones of the two cell lines were heterogeneous and did not correlate with their GSH values.

Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Survival; Chlorambucil; Cyclophosphamide; Doxorubicin; Drug Resistance; Fluorouracil; Glutathione; Humans; Melphalan; Radiation Tolerance; Semustine; Stomach Neoplasms; Tumor Cells, Cultured

A clone of a human gastric carcinoma cell line was used to determine whether cells which had survived a treatment with Melphalan would express altered survival responses when treated again with this agent 1 week or more later. Cells were treated for 1 h each week with 2 micrograms/ml (99% lethal dose). After the first Melphalan treatment, the cells exhibited a 10-fold reduction in sensitivity to Melphalan. This was preceded by a 2-fold increase in intracellular glutathione content. By the end of 10 weekly treatments, the cells were 50 times more resistant than controls (based on changes in survival fractions). They also demonstrated collateral resistance to Actinomycin D, 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea, galactitol, and X-rays, but showed no change in sensitivity to 5-fluorouracil, bleomycin, and Adriamycin. The resistance to Melphalan was not reversible when treatment was withheld for 4 weeks on two different occasions. The results suggest that treatment with a high dose of Melphalan either selects an existing population of cells with a high GSH content or induces mutations leading to increased GSH content or both, and this results in the expression of greater Melphalan resistance at the time of other treatments. Furthermore, Melphalan treatment stimulates a 50% increase in GSH content in resistant cells in just 6 h, an 85% increase in 36 h, and a 150% increase in 72 h. L-Buthionine sulfoximine partially reversed the expression of resistance to Melphalan by inducing a 60% reduction in intracellular glutathione content.

Topics: Buthionine Sulfoximine; Cell Cycle; Cell Survival; Drug Screening Assays, Antitumor; Glutathione; Humans; Melphalan; Methionine Sulfoximine; Stomach Neoplasms; Time Factors; Tumor Cells, Cultured

As the dose-limiting toxicity of mitoxantrone is hematological, the drug is suitable for dose escalation and use in intensive chemotherapy followed by autologous bone marrow rescue. Adult patients with therapy-resistant solid tumors received a regimen of high-dose cyclophosphamide (7 g/m2) and escalating doses of mitoxantrone in dose steps of 30, 45, 60, and 75 mg/m2. Both drugs were given i.v. on 3 consecutive days. Despite the addition of mesnum (3.5 to 7 g/m2), hemorrhagic cystitis occurred on the second day in four of eight patients, irrespective of the mesnum or mitoxantrone dose. Therefore, the cyclophosphamide in the combination regimen was replaced by high-dose melphalan (180 mg/m2). Mucositis was dose limiting at 75 mg/m2 of mitoxantrone. Responses were seen in eight of ten evaluable patients with four complete responses. Three responders received, after the autologous bone marrow transplantation program, radiotherapy or surgery on pretreatment bulky tumor localizations. Five patients still have disease-free survival after 9 to 36 mo. Pharmacokinetic studies of mitoxantrone were performed by high-performance liquid chromatography with UV detection. The plasma disappearance of mitoxantrone fitted into a three-compartment model with a mean t1/2 alpha of 10 min, a mean t1/2 beta of 96 min, and a slow elimination phase of 172 h. The mean distribution volume was 4294 +/- 3836 liters. We conclude that the high-dose cyclophosphamide-mitoxantrone regimen led to unexpected bladder toxicity, but the combination of melphalan (180 mg/m2) and mitoxantrone (60 mg/m2) can probably be given without major extramedullary toxicity. However, more patients should be evaluated at this dose before definite conclusions can be drawn about toxicity.

Topics: Adult; Bone Marrow Transplantation; Breast Neoplasms; Cyclophosphamide; Female; Humans; Male; Melphalan; Middle Aged; Mitoxantrone; Neoplasms; Neoplasms, Germ Cell and Embryonal; Ovarian Neoplasms; Stomach Neoplasms

Topics: Adenocarcinoma; Administration, Oral; Aged; Antineoplastic Agents; Carcinoma, Hepatocellular; Drug Combinations; Drug Evaluation; Female; gamma-Globulins; Humans; Immunotoxins; Liver Neoplasms; Male; Melphalan; Middle Aged; Stomach Neoplasms

Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cisplatin; Colonic Neoplasms; Combined Modality Therapy; Female; Head and Neck Neoplasms; Humans; Levamisole; Lung Neoplasms; Melphalan; Neoplasms; Postoperative Care; Stomach Neoplasms

K18 is a new drug produced by a combination of Melphalan and human immunoglobulin. K18 produced an inhibitory effect on the proliferation of human gastric and colon cancer transplanted in to nude mice. Also, combination effects of K18 with MMC and 5-FU were recognized in the same system. In a study of distribution after K18 administration, the accumulation and retention of this drug in the tumor region were observed. In the case of Melphalan administration, these phenomena were not observed. The antitumor activity of tumor homogenate was evaluated using a colony-forming assay with KB cells. As to the Melphalan-treated group, a four-hour homogenate reduced the number of colonies but a 48-h one did not. In the K18-treated group, the four-hour homogenate decreased the number slightly and the decrease became obvious with 48-h homogenate. In cell cycle analysis using K18 or Melphalan administration, gathering of S-phase cells was observed, but these changes appeared later with K18 than with Melphalan. This result showed that the effect of K18 was produced by the alkylating activity of Melphalan which was combined with immunoglobulin. For clinical application, K18 was administered to cancer patients at a dose of 60-90 mg every day. Two cases of good response were achieved. No side effect was observed. This remarkable efficacy and low degree of side effects in clinical application is probably due to the higher affinity and accumulation of K18 in the tumor region. K18 is a useful new drug for clinical application alone, or in combination with other chemotherapeutic drugs.

Topics: Animals; Antineoplastic Agents; Cell Cycle; Cell Line; Drug Combinations; Drug Synergism; Fluorouracil; gamma-Globulins; Humans; Immunotoxins; Melphalan; Mice; Mice, Nude; Mitomycin; Mitomycins; Neoplasm Transplantation; Stomach Neoplasms; Tissue Distribution

We administered melphalan by the intraperitoneal route to investigate its toxicity and pharmacokinetics. The drug was instilled with 2 litres of fluid and allowed to dwell in the peritoneal cavity for 4 hours. No local toxicity was detected by clinical examination, laboratory tests, or histologic examination. The intraperitoneal route allowed the dose to be increased to approximately three times the maximum dose tolerated intravenously before drug leaking into the systemic circulation produced dose-limiting myelosuppression. The peak peritoneal concentration averaged 93-fold greater than the plasma concentration, and total drug exposure for the peritoneal cavity averaged 63-fold greater than that for plasma. Tumor regressions were observed in patients with ovarian carcinoma and gastrointestinal adenocarcinomas. This study shows that from the pharmacologic point of view, if any portion of the tumor can be reached by intraperitoneal instillation, then there is a very strong rationale for the administration of melphalan by the intraperitoneal route, rather than the oral or intravenous route, for the treatment of tumors confined to the peritoneal cavity.

Topics: Adult; Aged; Ascites; Ascitic Fluid; Bone Marrow Diseases; Colonic Neoplasms; Female; Humans; Infusions, Parenteral; Kinetics; Laparotomy; Male; Melphalan; Middle Aged; Models, Biological; Neoplasms; Ovarian Neoplasms; Pancreatic Neoplasms; Peritoneal Cavity; Stomach Neoplasms

Topics: Animals; Colonic Neoplasms; Cyclophosphamide; Dog Diseases; Dogs; Drug Therapy, Combination; Female; Gastric Mucosa; Male; Melphalan; Plasmacytoma; Prednisone; Stomach Neoplasms

Chromosome aberrations were studied in peripheral lymphocytes from 50 patients treated with melphalan against ovarian carcinoma. The chromosome analyses were carried out 4-132 months (mean 57 months) after the end of melphalan therapy. Most of the patients were studied several times during four years. The mean frequency of cells with chromosome and chromatid aberrations was 5.4% in the patients and 2.3% in an untreated control group. The highest aberration frequency (average 18%) was found in a patient who later developed gastric carcinoma. The dominating types of aberrations in the patients were chromosome exchanges occurring as single marker chromosomes or as multiple chromosome rearrangements. These types of aberrations were found in only 0.3% of the control cells as compared to 3.8% of the patient cells. Patients with a high total dose of melphalan (above 420 mg) and a long duration of the therapy (average 22.5 months) had a higher frequency of cells with aberrations (6.3%) than patients with a lower total dose (below 420 mg) and a shorter therapy (12 months) (4.2%). No additive effect of radiation therapy was observed on the aberration frequency.

Topics: Adult; Aged; Chromosome Aberrations; Dose-Response Relationship, Drug; Female; Humans; Lymphocytes; Melphalan; Middle Aged; Ovarian Neoplasms; Stomach Neoplasms; Time Factors

The sensitivity of adenocarcinomas of the stomach to various cytostatic drugs has been tested in short-term incubations. A suspension of single cells and small tissue fragments was prepared. It was used for incubation with the following drugs: melphalan, vinblastine sulphate, amethopterin, and 5-fluoro-uracil. The effect of the cytostatic drugs was measured as the difference in incorporation of labelled precursors in treated tubes and untreated control tubes. The different tumours were found to vary significantly in the their sensitivity. Moreover, a correlation of the effects between melphalan and vinblastine sulphate, and between amethopterin and vinblastine sulphate was observed.

Topics: Adenocarcinoma; Antineoplastic Agents; Cells, Cultured; Depression, Chemical; DNA, Neoplasm; Fluorouracil; Humans; In Vitro Techniques; Melphalan; Methotrexate; Stomach Neoplasms; Thymidine; Tritium; Uridine; Vinblastine

In the present paper a test model was used to examine if human adenocarcinomas of the colon and the stomach are heterogenous as regards the sensitivity to cytosine arabinoside, melphalan, vinblastine sulphate, amethopterin and 5-fluorouracil in vitro. The effects of the five drugs were measured as the differences in incorporation of tritiated thymidine and deoxyuridine in drug-containing tubes and control tubes. It was found, that different parts of eleven colon and five stomach cancers differ significantly in their sensitivity to the same cytostatic treatment in vitro.

Topics: Adenocarcinoma; Antineoplastic Agents; Colonic Neoplasms; Cytarabine; Fluorouracil; Humans; Melphalan; Methotrexate; Stomach Neoplasms; Vinblastine

Topics: Animals; Benzene Derivatives; Chemotherapy, Cancer, Regional Perfusion; Drug Therapy, Combination; Fluorouracil; Humans; Injections, Intra-Arterial; Melphalan; Stomach Neoplasms; Thiotepa

Topics: Adult; Bone Neoplasms; Gastroscopy; Humans; Male; Melphalan; Multiple Myeloma; Plasmacytoma; Radiography; Stomach Neoplasms

Topics: Animals; Antibody Formation; Basophils; Cross Reactions; Dysgerminoma; Erythrocytes; Esophageal Neoplasms; Fluorouracil; Hemagglutination Tests; Humans; Immunization; Immunologic Techniques; Injections, Intradermal; Injections, Intravenous; Male; Melphalan; Rabbits; Rats; Stomach Neoplasms; Time Factors

Topics: Adenocarcinoma; Gastrectomy; Humans; Male; Melphalan; Middle Aged; Multiple Myeloma; Stomach Neoplasms

Topics: Chemotherapy, Cancer, Regional Perfusion; Fluorouracil; Humans; Injections, Intra-Arterial; Melphalan; Stomach Neoplasms; USSR

This work discusses the experience of one surgical team in the Third Surgical Unit at the Republican Teaching Hospital, Baghdad, from 1967 to 1970. 112 patients with advanced malignant lesions in various parts of the body were dealt with. In 84, the intra-arterial route was adopted; in the remaining, systemic administration of cytotoxic agents either singly or in combination was employed. The results are reported in terms of subjective and objective response, and the various complications are discussed.

Topics: Antineoplastic Agents; Breast Neoplasms; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Female; Head and Neck Neoplasms; Humans; Injections, Intra-Arterial; Iraq; Male; Melphalan; Methotrexate; Mouth Neoplasms; Podophyllin; Stomach Neoplasms; Urogenital Neoplasms

Topics: Administration, Oral; Adolescent; Aged; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Female; Fibrosarcoma; Humans; Knee; Lymphoma, Large B-Cell, Diffuse; Lymphoma, Non-Hodgkin; Male; Melphalan; Middle Aged; Retroperitoneal Neoplasms; Sarcoma; Stomach Neoplasms

Topics: Anemia; Fluorouracil; Humans; Leukopenia; Melphalan; Nitrogen Mustard Compounds; Stomach Neoplasms; Thiotepa; Thrombocytopenia

Topics: Adenine; Carbon Isotopes; Culture Techniques; Female; Hemangiosarcoma; Humans; Lysine; Melphalan; Mesenchymoma; Neoplasm Proteins; Ovarian Neoplasms; Pancreatic Neoplasms; RNA, Neoplasm; Stomach Neoplasms; Uridine

Topics: Animals; Chick Embryo; Culture Techniques; Female; Gonads; Humans; Liver Neoplasms; Male; Melphalan; Neoplasm Metastasis; Ovary; Stomach Neoplasms; Testis

Topics: Antineoplastic Agents; Chemotherapy, Cancer, Regional Perfusion; Cyclophosphamide; Fluorouracil; Humans; Injections, Intra-Arterial; Melphalan; Methods; Stomach Neoplasms; Thiotepa

Topics: Animals; Chick Embryo; Culture Techniques; Female; Germ Cells; Gonads; Humans; Male; Melphalan; Ovary; Stomach Neoplasms; Testis

Topics: Aged; Alkylating Agents; Female; Humans; Injections, Intra-Arterial; Male; Melphalan; Methods; Stomach Neoplasms; Uracil

Topics: Animals; Chemotherapy, Cancer, Regional Perfusion; Dogs; Fluorouracil; Melphalan; Stomach Diseases; Stomach Neoplasms

Topics: Adenocarcinoma; Aged; Antineoplastic Agents; Female; Humans; Lymphoma, Large B-Cell, Diffuse; Male; Melphalan; Middle Aged; Stomach Neoplasms

Topics: Adenocarcinoma; Adenocarcinoma, Mucinous; Adenocarcinoma, Scirrhous; Antibiotics, Antineoplastic; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Squamous Cell; Culture Techniques; Flavonoids; Fluorouracil; HeLa Cells; Humans; Lung Neoplasms; Melphalan; Mercaptopurine; Methods; Mitomycins; Neoplasms; Rectal Neoplasms; Stomach Neoplasms

Topics: Adenocarcinoma; Aged; Breast Neoplasms; Colonic Neoplasms; Cyclophosphamide; Female; Hodgkin Disease; Humans; Intestinal Neoplasms; Liver Neoplasms; Male; Melphalan; Middle Aged; Neoplasms; Palliative Care; Stomach Neoplasms; Thiotepa

Topics: Administration, Oral; Antineoplastic Agents; Demecolcine; Drug Synergism; Esophagus; Gastrointestinal Neoplasms; Geriatrics; Humans; Melphalan; Neoplasms; Palliative Care; Rectum; Stomach Neoplasms